Table 2.

Blinatumomab for ALL

ReferenceContextNMedian age (range), yRemission rate (CR/CRh)MRD-negative rate (among responders)Survival (median follow-up, mo)Salvaged to transplant
Topp et al. (28, 29)Phase II: MRD-positive adult ALL2147 (20–77)80%RFS, 65% (33 mo)50%
Goekbuget et al. (30)aPhase II: MRD-positive adult ALL11645 (18–76)80%NANA
Topp et al. (31)Phase II: Adult RR-ALL3632 (18–77)69%88%OS, 9.8 mo (12.1 mo)52%
RFS, 7.6 mo (9.7 mo)
Topp et al. (32)Phase II: Adult RR-ALL18939 (18–79)43%82%OS, 6.1 mo (9.8 mo)40%
RFS, 5.9 mo (8.9 mo)
von Stackelberg et al. (24)aPhase I: Pediatric RR-ALL41<18 y32%77%OS, 5.7 mo69%
RFS, 8.3 mo (12.4 mo)
Gore et al. (35)aPhase I–II: Pediatric RR-ALL399 (2–16)31%42%OS, 4.3 mo (6 mo)50%
RFS, 5.6 mo
  • aPresented in abstract form.